Understand the source comparison
PE-22-28 Dosage Neurogenesis 2026: Protocol Comparison
Acute Cognitive Enhancement 10–15mg Single dose 60–90 min pre-task Learning consolidation, spatial memory testing Effects measurable 2–6 hours post-dose Best for isolated cognitive tasks; not sustained neuroplasticity Chronic Neuroplasticity (Standard) 15–25mg
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Acute Cognitive Enhancement
- 10–15mg
- Single dose 60–90 min pre-task
- Learning consolidation, spatial memory testing
- Effects measurable 2–6 hours post-dose
- Best for isolated cognitive tasks; not sustained neuroplasticity
- Chronic Neuroplasticity (Standard)
- 15–25mg
- 2–3x weekly
- Hippocampal volume increase, synaptic density
- Measurable changes at 4–8 weeks
- Gold standard for neurogenesis research; most published data uses this range
- High-Dose Exploration
- 30–40mg
- 2x weekly
- Testing upper therapeutic threshold
- Variable; some models show plateau at 6 weeks
- Marginal benefit over 25mg; increased off-target risk without added neurogenesis
- Combination Stack (PE-22-28 + P21)
- 10–15mg PE-22-28 + 1–2mg P21
- 3x weekly
- Dual NGF and BDNF pathway activation
- Synergistic effects observed at 3–6 weeks
- Allows lower PE-22-28 dose; mechanistically sound but limited human data
- Bodyweight-Scaled
- 0.2–0.35mg/kg
- Individualised dosing based on allometric scaling
- Standard 4–8 week timeline
- Most physiologically rational; avoids fixed-dose errors in varied bodyweights